Horizon Investment Services LLC Purchases Shares of 17,621 Globus Medical, Inc. $GMED

Horizon Investment Services LLC purchased a new stake in Globus Medical, Inc. (NYSE:GMED) during the 4th quarter, Holdings Channel.com reports. The fund purchased 17,621 shares of the medical device company’s stock, valued at approximately $1,538,000.

Several other hedge funds also recently added to or reduced their stakes in GMED. Advisory Services Network LLC purchased a new position in Globus Medical in the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC increased its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the last quarter. SBI Securities Co. Ltd. grew its position in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC grew its position in shares of Globus Medical by 485.4% during the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after acquiring an additional 631 shares during the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GMED. Barclays raised their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Needham & Company LLC raised their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wells Fargo & Company lowered their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Piper Sandler restated an “overweight” rating on shares of Globus Medical in a research report on Tuesday. Finally, Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $106.36.

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 18.38% of the stock is currently owned by company insiders.

Globus Medical Price Performance

NYSE:GMED opened at $80.44 on Friday. The firm’s fifty day moving average price is $85.77 and its 200 day moving average price is $88.10. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The firm has a market cap of $10.92 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 1.66 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same period last year, the firm posted $0.68 EPS. Globus Medical’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.